Compared to Estimates, Walgreens (WBA) Q3 Earnings: A Look at Key Metrics

Walgreens Boots Alliance (WBA) reported Q3 May 2025 revenue of $38.99 billion, a 7.3% year-over-year increase, exceeding the Zacks Consensus Estimate by 6.49%. While diluted EPS of $0.38 also surpassed estimates by 11.76%, it marked a notable decline from $0.63 a year ago. Segmental performance was mixed, with U.S. Retail Pharmacy and International revenues and operating income significantly beating expectations, largely offsetting a slight miss in U.S. Healthcare revenue and operating income. Despite the overall revenue beat, WBA shares underperformed the S&P 500 over the past month, returning +1.1% against the index's +5.1%.

Analysis

Walgreens Boots Alliance (WBA) delivered a mixed Q3 performance characterized by strong top-line results that mask underlying profitability concerns. The company reported revenue of $38.99 billion, a 7.3% year-over-year increase that surpassed the Zacks Consensus Estimate by 6.49%. Similarly, EPS of $0.38 beat expectations by 11.76%. However, this EPS figure represents a steep 39.7% decline from the $0.63 reported in the prior-year quarter, indicating significant margin pressure. A segmental breakdown reveals that the beat was driven by the core U.S. Retail Pharmacy and International divisions, which exceeded revenue estimates and posted substantial adjusted operating income surprises; notably, U.S. Retail Pharmacy operating income came in at $350 million, more than triple the $113.67 million estimate. This strength was offset by weakness in the strategic U.S. Healthcare segment, which missed revenue and operating income forecasts and contracted 1.1% year-over-year. Despite the earnings beat, the stock's 1.1% return over the past month has significantly lagged the S&P 500's 5.1% gain, suggesting investor apprehension about the quality of earnings and the viability of the healthcare growth strategy.

Key Decisions for Investors

• Investors should scrutinize the sustainability of the earnings beat, as it was driven by outperformance in mature segments while the strategic U.S. Healthcare division showed contraction and missed expectations, posing a risk to the long-term growth thesis.
• The significant year-over-year decline in EPS from $0.63 to $0.38, despite a 7.3% revenue increase, warrants a deep dive into the company's margin structure and cost controls, as top-line growth is currently not translating to improved profitability.
• Given the stock's material underperformance compared to the broader market despite the positive headline surprises, it may be prudent to assess whether the market is correctly pricing in long-term margin erosion or if the operational strength in the core pharmacy business presents a value opportunity.